Guest guest Posted September 29, 2011 Report Share Posted September 29, 2011 This is an article comparing the two new drugs for Hep C. It is also about the stock but does give other info that is interesting. I was not aware that one drug had better SVR rates than the other in clinical trials. If you are planning to treat, you might want to read it. Subject: ANALYSIS-Vertex takes early rounds of hep C bout with Merck - AlertNet http://www.trust.org/alertnet/news/analysis-vertex-takes-early-rounds-of-hep-c-bout-with-merck#.ToVUk3EfC-0.email--- Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.